Breakthrough liver fluke drug shows promise in largest safety trial yet
NCT ID NCT04230148
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study tested the safety and effectiveness of EGATEN (triclabendazole) in 301 people aged 6 and older with fascioliasis, a parasitic liver infection. Participants received two doses of the drug 12 hours apart and were monitored for 90 days. The goal was to see if the treatment safely cures the infection without needing long-term medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FASCIOLIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Medellín, Antioquia, 050010, Colombia
-
Novartis Investigative Site
Alexandria, 21131, Egypt
-
Novartis Investigative Site
Cairo, 11617, Egypt
-
Novartis Investigative Site
San Martín de Porres, Lima region, 31, Peru
-
Novartis Investigative Site
Cusco, 84, Peru
-
Novartis Investigative Site
Istanbul, Fatih, 34093, Turkey (Türkiye)
-
Novartis Investigative Site
Gaziantep, Sehitkamil, 27310, Turkey (Türkiye)
-
Novartis Investigative Site
Sur, 21280, Turkey (Türkiye)
-
Novartis Investigative Site
Van, 65080, Turkey (Türkiye)
-
Novartis Investigative Site
Qui Nhon, Binh Dinh, 590000, Vietnam
Conditions
Explore the condition pages connected to this study.